Ordering
Available Variants10 mg
CHA.74674-10mg
Price
€126.40
Available – Dispatch in 14 days
50 mg
CHA.74674-50mg
Price
€411.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.74674-10mg | €126.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.74674-50mg | €411.20 |
≥98% (HPLC), nonsteroidal aromatase inhibitor, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C14H13N3·HCl |
|---|---|
| CAS Number | 102676-31-3 |
| Molecular Weight | 259.73 |
| UNSPSC Code | 51111800 |
| PubChem Substance ID | 329799706 |
| NACRES | NA.77 |
| MDL number | MFCD00866239 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS06
GHS08
  GHS06,GHS08
|
|---|---|
| signalword | Danger |
| hcodes | H301,H361 |
| pcodes | P202 - P264 - P280 - P301 + P310 - P405 - P501 |
| Hazard Classifications | Acute Tox. 3 Oral - Repr. 2 |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 2 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | dust mask type N95 (US), Eyeshields, Faceshields, Gloves |
Technical Overview & Applications Use-case context
Fadrozole hydrochloride, with a CAS number of 102676-47-1, is a synthetic steroid compound that functions as an aromatase inhibitor. Aromatase is an enzyme responsible for the conversion of androgens to estrogens, and by inhibiting this enzyme, fadrozole hydrochloride reduces estrogen production in the body. This mechanism of action makes it a potential therapeutic agent for the treatment of estrogen-dependent conditions, such as breast cancer and endometriosis. Fadrozole hydrochloride has been investigated in various preclinical and clinical studies, demonstrating its efficacy in decreasing estrogen levels and exhibiting anti-tumor activity. As a result, it has garnered interest as a possible treatment option for hormone-sensitive cancers and other disorders characterized by excessive estrogen production, highlighting its potential as a valuable pharmacological tool in the management of these conditions. Further research is necessary to fully explore its therapeutic potential.
